SCHEMBL93662

SCHEMBL93662

Cc1ccc(C(=O)NO)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC6 Q9UBN7 7/20 1.00
HDAC1 Q13547 6/20 1.00
ALDH1A1 P00352 3/20 0.70
GAA P10253 1/20 0.70
HDAC8 Q9BY41 4/20 0.67
HDAC2 Q92769 3/20 0.67
NPC1 O15118 1/20 0.61
RAB9A P51151 1/20 0.61
CA1 P00915 2/20 0.59
CA2 P00918 1/20 0.59
HDAC3 O15379 2/20 0.58
CA12 O43570 1/20 0.58
IDO1 P14902 1/20 0.58
ALOX15 P16050 1/20 0.58
CA9 Q16790 1/20 0.58
HDAC7 Q8WUI4 1/20 0.58
HSD17B10 Q99714 1/20 0.58
NCOR2 Q9Y618 1/20 0.58
LMNA P02545 1/20 0.56
CES2 O00748 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12620628 0.88 HDAC6 (0.77) HDAC6HDAC1ALDH1A1GAAHDAC8
SCHEMBL676148 0.88 RAB9A (0.85) HDAC6HDAC1ALDH1A1HDAC8HDAC2
SCHEMBL21628916 0.88 HDAC6 (0.77) HDAC6HDAC1ALDH1A1GAAHDAC8
SCHEMBL3673435 0.87 HDAC6 (0.75) HDAC6HDAC1HDAC8HDAC2CA1
SCHEMBL19193084 0.86 HDAC6 (0.74) HDAC6HDAC1ALDH1A1GAAHDAC8
SCHEMBL12620650 0.86 HDAC6 (0.74) HDAC6HDAC1ALDH1A1GAAHDAC8
SCHEMBL7103221 0.82 ALDH1A1 (1.00) HDAC6HDAC1ALDH1A1GAANPC1
SCHEMBL2567668 0.82 ALDH1A1 (0.73) HDAC6HDAC1ALDH1A1GAANPC1
SCHEMBL5691186 0.82 ALDH1A1 (0.73) HDAC6HDAC1ALDH1A1GAANPC1
SCHEMBL5391604 0.82 HDAC6 (0.67) HDAC6HDAC1ALDH1A1GAAHDAC8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 95 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11981648-B2 Method for the synthesis of 3-R-1,4,2-dioxazol-5-ones TESLA, INC. (US) 2024-05-14 US claimed
CN-114195772-B 1,2, 4-oxadiazole derivative containing 1,3, 4-thiadiazole unit, and preparation method and application thereof 贵州大学 2023-06-30 CN claimed
US-20230029852-A1 METHOD FOR THE SYNTHESIS OF 3-R-1,4,2-DIOXAZOL-5-ONES PANASONIC HOLDINGS CORPORATION (JP) 2023-02-02 US claimed
CN-110653071-B Rare earth collecting agent and preparation method thereof 内蒙古包钢稀土林峰科技有限公司 2021-06-29 CN claimed
CN-110653071-A Rare earth collecting agent and preparation method thereof 内蒙古包钢稀土林峰科技有限公司 2020-01-07 CN claimed
EP-1461010-A2 HYDROXAMIC ACID AND ITS DERIVATIVES AS INHIBITORS OF MELANOCYTE TYROSINASE FOR TOPICAL SKIN LIGHTENERS Integriderm, Inc. (US) 2004-09-29 EP claimed
US-20030199558-A1 Hydroxamic acid and its derivatives as inhibitors of melanocyte tyrosinase for topical skin lighteners INTEGRIDERM, INC. 2003-10-23 US claimed
WO-2003057184-A2 HYDROXAMIC ACID AND ITS DERIVATIVES AS INHIBITORS OF MELANOCYTE TYROSINASE FOR TOPICAL SKIN LIGHTENERS INTEGRIDERM, INC. (US) 2003-07-17 WO claimed
US-20250297134-A1 HIGH RATE BULK OXIDE CMP COMPOSITION ENTEGRIS, INC. 2025-09-25 US disclosed
CN-119591676-A Lipopeptide HIV membrane fusion inhibitor and pharmaceutical application 中国医学科学院病原生物学研究所 2025-03-11 CN disclosed
CN-118724753-A Method for promoting synthesis of hydroxamic acid by using metal salt 沈阳药科大学 2024-10-01 CN disclosed
WO-2024123929-A1 DEVELOPMENT OF POTENT DUAL HDAC/BRD4 INHIBITORS BIOVENTURES, LLC (US) 2024-06-13 WO disclosed
CN-115160097-B Method for synthesizing amide by reducing N-O bond by thioacetic acid 温州大学 2024-05-28 CN disclosed
CN-118027033-A HDAC6 inhibitor, preparation method thereof and application thereof in anti-inflammatory and ulcerative colitis 四川大学 2024-05-14 CN disclosed
EP-1461010-A2 HYDROXAMIC ACID AND ITS DERIVATIVES AS INHIBITORS OF MELANOCYTE TYROSINASE FOR TOPICAL SKIN LIGHTENERS Integriderm, Inc. (US) 2004-09-29 EP disclosed
WO-2003057184-A2 HYDROXAMIC ACID AND ITS DERIVATIVES AS INHIBITORS OF MELANOCYTE TYROSINASE FOR TOPICAL SKIN LIGHTENERS INTEGRIDERM, INC. (US) 2003-07-17 WO disclosed
EP-1052661-A2 Metal complex dye for a photoelectrochemical cell FUJI PHOTO FILM CO., LTD. (JP) 2000-11-15 EP disclosed
US-4999366-A Treatment of hyperlipidemia THE NORTH CAROLINA CENTRAL UNIV. (US) 1991-03-12 US disclosed
US-4946963-A HYPOLIPIDEMIC AGENTS THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) 1990-08-07 US disclosed
EP-0321090-A2 Isoxazolidine-3,5-diones in the treatment of hyperlipidemia THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) 1989-06-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030199558-A1 Hydroxamic acid and its derivatives as inhibitors of melanocyte tyrosinase for topical skin lighteners TYR, MC1R, MITF HDAC6 647/4885HDAC1 466/4885ALDH1A1 306/4885
US-11981648-B2 Method for the synthesis of 3-R-1,4,2-dioxazol-5-ones CYP4X1, DDO, CYP4B1 HDAC6 1947/4885HDAC1 1595/4885ALDH1A1 269/4885
US-20230029852-A1 METHOD FOR THE SYNTHESIS OF 3-R-1,4,2-DIOXAZOL-5-ONES CYP4X1, DDO, CYP4B1 HDAC6 1947/4885HDAC1 1595/4885ALDH1A1 269/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.